Valneva SE is a specialty vaccine company focused on developing and commercializing innovative vaccines for infectious diseases
The company is committed to addressing significant unmet medical needs through its diverse pipeline of vaccine candidates, which includes programs for diseases such as Lyme disease and chikungunya. Valneva employs advanced technologies and extensive research to create safe and effective vaccines that aim to improve public health outcomes globally. By collaborating with various health organizations and leveraging its expertise in vaccine development, Valneva seeks to contribute to the prevention of infectious diseases and foster better health through vaccination.
Valneva reports long-lasting antibody persistence in its chikungunya vaccine three years post-dose, supporting its global approvals and expansion efforts.
Valneva and Pfizer released data from their Phase 2 study of the Lyme disease vaccine candidate VLA15, showing strong immune response and safety profile after a second booster dose, with seroconversion rates above 90% in all age groups.
Pfizer and Valneva announced the completion of the primary vaccination series in the Phase 3 VALOR trial for their Lyme disease vaccine, VLA15. Participants will be monitored until the end of the 2025 Lyme disease season. Marketing applications are planned for 2026.
Valneva released positive Phase 3 data for its single-shot chikungunya virus vaccine in adolescents. The vaccine is also expected to be approved for use in Brazil.
